Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | ESRRG | P62508 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196799 | 0.85 | MEN1 (0.48) | MEN1KMT2AHSD11B1ESR1ESR2 | |
| SCHEMBL5758950 | 0.79 | APP (0.37) | APPMEN1KMT2AESR1ESR2 | |
| SCHEMBL7129323 | 0.79 | APP (0.37) | APPMEN1KMT2AESR1ESR2 | |
| SCHEMBL13141988 | 0.77 | ESR1 (0.52) | APPMEN1KMT2AESR1ESR2 | |
| SCHEMBL3096756 | 0.77 | SLC2A1 (0.46) | APPTPMTTRPV1CA1CA2 | |
| SCHEMBL8985984 | 0.77 | MEN1 (0.42) | MEN1KMT2AHSD11B1ESR1ESR2 | |
| SCHEMBL1538300 | 0.77 | APP (0.42) | APPMEN1KMT2AESR1ESR2 | |
| SCHEMBL10620533 | 0.77 | LMNA (0.60) | MEN1KMT2AHPGDHSD17B10LMNA | |
| SCHEMBL18802754 | 0.77 | KIF11 (0.44) | MEN1KMT2AHSD11B1ESR1ESR2 | |
| SCHEMBL15108873 | 0.77 | APP (0.42) | APPESR1ESR2HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025079648-A1 | COMPOUND, COMPOSITION, RESIN COMPOSITION, COMPOSITION FOR FORMING FILM, COMPOSITION FOR FORMING FILM FOR LITHOGRAPHY, AND COMPOSITION FOR FORMING RESIST FILM | 三菱瓦斯化学株式会社 | 2025-04-17 | — | — | WO | disclosed |
| WO-2024190386-A1 | RADIATION-SENSITIVE COMPOSITION, RESIST PATTERN FORMATION METHOD, POLYMER, AND COMPOUND | JSR株式会社 | 2024-09-19 | — | — | WO | disclosed |
| WO-2024142681-A1 | RADIATION-SENSITIVE COMPOSITION AND METHOD FOR FORMING RESIST PATTERN | JSR株式会社 | 2024-07-04 | — | — | WO | disclosed |
| WO-2023140231-A1 | RESIST COMPOSITION, METHOD FOR FORMING RESIST PATTERN, AND COMPOUND | 東京応化工業株式会社 | 2023-07-27 | — | — | WO | disclosed |
| CN-114685243-B | Green and efficient preparation method of 2-phenyl-2-propanol series compounds | 大连理工大学 | 2023-02-07 | — | — | CN | disclosed |
| CN-114685243-A | Green and efficient preparation method of 2-phenyl-2-propanol series compounds | 大连理工大学 | 2022-07-01 | — | — | CN | disclosed |
| US-20220146931-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11142527-B2 | Dihydropyrimidine compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| CN-112533913-A | Novel compounds | 英夫拉索姆有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3788041-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-03-10 | — | — | EP | disclosed |
| US-20040143117-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2004-07-22 | — | — | US | disclosed |
| US-20040106540-A1 | Method of treating cancer | BARNETT STANLEY F (US) | 2004-06-03 | — | — | US | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1379251-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1379250-A2 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003084473-A2 | METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2002083064-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083138-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-4017543-A | ANTIARRHYTHMIA | MERCK & CO., INC. (US) | 1977-04-12 | — | — | US | disclosed |
| US-3957871-A | ANTIARRHYTHMIA AGENTS, UNSATURATED AROMATIC AMINES | MERCK & CO., INC. (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142527-B2 | Dihydropyrimidine compounds and uses thereof in medicine | DPYD, SLC10A1, DHODH | APP 388/4885MEN1 1809/4885KMT2A 2794/4885 |
| US-20040143117-A1 | Inhibitors of akt activity | AKT1, AKT2, AKT3 | APP 3605/4885MEN1 2983/4885KMT2A 1352/4885 |
| US-20220146931-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | RER1, FGFR1, CLIC1 | APP 3354/4885MEN1 1618/4885KMT2A 1664/4885 |
| US-20040102360-A1 | Combination therapy | MTOR, AKT2, PLK1 | APP 4055/4885MEN1 720/4885KMT2A 1485/4885 |
| US-20040106540-A1 | Method of treating cancer | PACSIN2, CTTN, PLK1 | APP 4594/4885MEN1 1656/4885KMT2A 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.